The Efficacy and Safety of a Fixed Combination of Chinese Herbal Medicine in Chronic Urticaria: A Randomized, Double-Blind, Placebo-Controlled Pilot Study

Sien-Hung Yang, Yi-Hsuan Lin, Jr-Rung Lin, Hsing-Yu Chen, Sindy Hu, Yi-Han Yang, Yi-Hsun Yang, Yin-Shuo Yang, Yao-Fan Fang, Sien-Hung Yang, Yi-Hsuan Lin, Jr-Rung Lin, Hsing-Yu Chen, Sindy Hu, Yi-Han Yang, Yi-Hsun Yang, Yin-Shuo Yang, Yao-Fan Fang

Abstract

Background: Chronic urticaria is a bothersome skin disease, and Chinese herbal medicine (CHM) is commonly used as adjuvant therapy. This study aimed to evaluate the effectiveness and safety of the mixture of two CHM formula, Xiao-Feng-San (XFS) and Qing-Shang-Fang-Feng-Tang (QSFFT), in treating urticaria through a randomized, double-blind, placebo-controlled clinical trial. Methods: 78 participants entered the screening phase between November 2012 and August 2015. Participants were randomly and equally allocated in either CHM group (2 gm XFS and 2 gm QSFFT four times a day and 5 mg levocetirizine once daily for 28 days followed by 5 mg levocetirizine once daily alone for 28 days) or control group (placebo and 5 mg levocetirizine daily followed by 5 mg levocetirizine once daily for 28 days alone). Symptom improvement was set as the primary outcome, and the influence on sleep quality and changes in serum markers were used as secondary outcomes. Per protocol design was applied to the final analysis. Results: A total of 56 participants entered the final analysis stage. Participants in the CHM group had more prominent symptom relief on day 56 (the weekly urticaria activity score, UAS7, as 9.9 ± 9.2 vs. 15.6 ± 10.8, p = 0.038). In the CHM group, participants' symptom severity reduced progressively (trend analysis, p < 0.001) while the decreasing trend was less favored in the control group (trend analysis, p = 0.056). The life quality improved gradually in both groups, while the differences between CHM and control groups were statistically insignificant. For urticaria-related cytokines, interferon-γ seemed to decrease positively in the CHM group (about 30.8% reduction from baseline, trend analysis p = 0.013). For safety issue, the CHM prescription was well-tolerated with no noticeable long-term side effects when compared to the control group. At 6-month follow-up of symptom changes after the end of the trial, the CHM group participants reported positive results in no recurrence or ≥50% improvement (36.3% in CHM group vs. 20% in Control group, p = 0.103). Conclusions: The combination of XFS and QSFFT tended to be feasible and tolerable adjuvant therapy for urticaria in addition to standard therapy. However, larger study population with longer follow-up duration may be still needed. Trial registration: NCT01715740 (ClinicalTrials.gov).

Keywords: Chinese herbal medicine; chronic urticaria; clinical trial; double-blind; placebo-control; randomization.

Figures

Figure 1
Figure 1
Flow diagram of this study (revised from the Consolidated Standards of Reporting Trials guideline). CHM, Chinese herbal medicine.
Figure 2
Figure 2
Evolution of symptom severity of urticaria (*p-value < 0.05 between the CHM and control groups). UAS7, weekly urticaria activity score; CHM, Chinese herbal medicine.

References

    1. Akamatsu H., Asada Y., Horio T. (1998). Inhibitory effect of shofu-san, a Japanese kampo medicine, on neutrophil functions in vitro. Am. J. Chin. Med. 26, 57–64. 10.1142/S0192415X98000087
    1. Auyeung P., Mittag D., Hodgkin P. D., Harrison L. C. (2016). Autoreactive T cells in chronic spontaneous urticaria target the IgE Fc receptor Ialpha subunit. J. Allergy Clin. Immunol. 138, 761–768.e4. 10.1016/j.jaci.2016.04.036
    1. Beck L. A., Bernstein J. A., Maurer M. (2017). A review of international recommendations for the diagnosis and management of chronic urticaria. Acta Derm. Venereol. 97, 149–158. 10.2340/00015555-2496
    1. Bossi F., Frossi B., Radillo O., Cugno M., Tedeschi A., Riboldi P., et al. . (2011). Mast cells are critically involved in serum-mediated vascular leakage in chronic urticaria beyond high-affinity IgE receptor stimulation. Allergy 66, 1538–1545. 10.1111/j.1398-9995.2011.02704.x
    1. Cassano N., Raho G., Filieri M., D'argento V., Amoruso A., Filotico R., et al. . (2006). Influence of desloratadine on oxidative stress markers in patients with chronic idiopathic urticaria. Int. J. Dermatol. 45, 394–396. 10.1111/j.1365-4632.2006.02467.x
    1. Chang L. C., Huang N., Chou Y. J., Lee C. H., Kao F. Y., Huang Y. T. (2008). Utilization patterns of Chinese medicine and Western medicine under the National Health Insurance Program in Taiwan, a population-based study from 1997 to 2003. BMC Health Serv. Res. 8:170. 10.1186/1472-6963-8-170
    1. Chen H. Y., Lin Y. H., Chen Y. C. (2016). Identifying Chinese herbal medicine network for treating acne: Implications from a nationwide database. J. Ethnopharmacol. 179, 1–8. 10.1016/j.jep.2015.12.032
    1. Chen H. Y., Lin Y. H., Huang J. W., Chen Y. C. (2015). Chinese herbal medicine network and core treatments for allergic skin diseases: Implications from a nationwide database. J. Ethnopharmacol. 168, 260–267. 10.1016/j.jep.2015.04.002
    1. Chen H. Y., Lin Y. H., Wu J. C., Chen Y. C., Thien P. F., Chen T. J., et al. . (2012). Characteristics of pediatric traditional Chinese medicine users in Taiwan: a nationwide cohort study. Pediatrics 129, e1485–e1492. 10.1542/peds.2011-3008
    1. Chung K. F., Kan K. K., Yeung W. F. (2011). Assessing insomnia in adolescents: comparison of Insomnia Severity Index, Athens Insomnia Scale and Sleep Quality Index. Sleep Med. 12, 463–470. 10.1016/j.sleep.2010.09.019
    1. Dilek F., Ozceker D., Ozkaya E., Guler N., Tamay Z., Kesgin S., et al. . (2016). Oxidative stress in children with chronic spontaneous urticaria. Oxid. Med. Cell. Longev. 2016:3831071. 10.1155/2016/3831071
    1. Ferrer M. (2009). Epidemiology, healthcare, resources, use and clinical features of different types of urticaria. Alergologica 2005. J. Investig. Allergol. Clin. Immunol. 19(Suppl. 2), 21–26.
    1. Fine L. M., Bernstein J. A. (2016). Guideline of chronic urticaria beyond. Allergy Asthma Immunol. Res. 8, 396–403. 10.4168/aair.2016.8.5.396
    1. Finlay A. Y., Khan G. K. (1994). Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin. Exp. Dermatol. 19, 210–216. 10.1111/j.1365-2230.1994.tb01167.x
    1. Fung A. Y., Look P. C., Chong L. Y., But P. P., Wong E. (1999). A controlled trial of traditional Chinese herbal medicine in Chinese patients with recalcitrant atopic dermatitis. Int. J. Dermatol. 38, 387–392. 10.1046/j.1365-4362.1999.00732.x
    1. Gao X. K., Fuseda K., Shibata T., Tanaka H., Inagaki N., Nagai H. (2005). Kampo medicines for mite antigen-induced allergic dermatitis in NC/Nga mice. Evid. Based Complement. Alternat. Med. 2, 191–199. 10.1093/ecam/neh077
    1. Huang H., Yang P., Xue J., Tang J., Ding L., Ma Y., et al. . (2014). Evaluating the individualized treatment of traditional chinese medicine: a pilot study of N-of-1 trials. Evid. Based Complement. Alternat. Med. 2014:148730. 10.1155/2014/148730
    1. Kalaaji A. N., Wahner-Roedler D. L., Sood A., Chon T. Y., Loehrer L. L., Cha S. S., et al. . (2012). Use of complementary and alternative medicine by patients seen at the dermatology department of a tertiary care center. Complement. Ther. Clin. Pract. 18, 49–53. 10.1016/j.ctcp.2011.05.003
    1. Kaplan A. P. (2012). Treatment of chronic spontaneous urticaria. Allergy Asthma Immunol. Res. 4, 326–331. 10.4168/aair.2012.4.6.326
    1. Khalil S., Mcbride D., Gimenez-Arnau A., Grattan C., Balp M.-M., Stull D. E. (2015). Weekly urticaria activity score (UAS7) and dermatology life quality index (DLQI) in validation of chronic spontaneous/idiopathic urticaria (CSU/CIU) health states. J. Allergy Clin. Immunol. 135:AB131 10.1016/j.jaci.2014.12.1362
    1. Kulthanan K., Tuchinda P., Chularojanamontri L., Chanyachailert P., Korkij W., Chunharas A., et al. . (2016). Clinical practice guideline for diagnosis and management of urticaria. Asian Pac. J. Allergy Immunol. 34, 190–200.
    1. Lin Y. H., Chen Y. C., Hu S., Chen H. Y., Chen J. L., Yang S. H. (2013). Identifying core herbal treatments for urticaria using Taiwan's nationwide prescription database. J. Ethnopharmacol. 148, 556–562. 10.1016/j.jep.2013.04.052
    1. Long J. W., Wang Y. Y., Pi X. M., Tu Y. T. (2010). Clinical observation on the treatment of chronic urticaria with total glucosides of paeony capsule combined with citirizine. Chin. J. Integr. Med. 16, 353–356. 10.1007/s11655-010-0504-2
    1. Magerl M., Pisarevskaja D., Scheufele R., Zuberbier T., Maurer M. (2010). Effects of a pseudoallergen-free diet on chronic spontaneous urticaria: a prospective trial. Allergy 65, 78–83. 10.1111/j.1398-9995.2009.02130.x
    1. Maurer M., Rosen K., Hsieh H. J., Saini S., Grattan C., Gimenez-Arnau A., et al. (2013). Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N. Engl. J. Med. 368, 924–935. 10.1056/NEJMoa1215372
    1. Nettis E., Colanardi M. C., Barra L., Ferrannini A., Vacca A., Tursi A. (2006). Levocetirizine in the treatment of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Br. J. Dermatol. 154, 533–538. 10.1111/j.1365-2133.2005.07049.x
    1. Nose M., Sakushima J., Harada D., Ogihara Y. (1999). Comparison of immunopharmacological actions of 8 kinds of kampo-hozais clinically used in atopic dermatitis on delayed-type hypersensitivity in mice. Biol. Pharm. Bull. 22, 48–54. 10.1248/bpb.22.48
    1. Rimoldi M., Rossi O., Rota N. (2016). State of the art of chronic spontaneous urticaria in Italy: a multicentre survey to evaluate physicians' and patients' perspectives. BMJ Open 6:e012378. 10.1136/bmjopen-2016-012378
    1. Sagdic A., Sener O., Bulucu F., Karadurmus N., Yamanel L., Tasci C., et al. . (2011). Oxidative stress status in patients with chronic idiopathic urticaria. Allergol. Immunopathol. 39, 150–153. 10.1016/j.aller.2010.06.012
    1. Soldatos C. R., Dikeos D. G., Paparrigopoulos T. J. (2003). The diagnostic validity of the Athens Insomnia Scale. J. Psychosom. Res. 55, 263–267. 10.1016/S0022-3999(02)00604-9
    1. Takeda T., Sakurai Y., Takahagi S., Kato J., Yoshida K., Yoshioka A., et al. . (2011). Increase of coagulation potential in chronic spontaneous urticaria. Allergy 66, 428–433. 10.1111/j.1398-9995.2010.02506.x
    1. Teschke R., Eickhoff A. (2015). Herbal hepatotoxicity in traditional and modern medicine: actual key issues and new encouraging steps. Front. Pharmacol. 6:72. 10.3389/fphar.2015.00072
    1. Vichyanond P. (2011). Omalizumab in allergic diseases, a recent review. Asian Pac. J. Allergy Immunol. 29, 209–219.
    1. Werner S. M. (2014). Patient safety and the widespread use of herbs and supplements. Front. Pharmacol. 5:142. 10.3389/fphar.2014.00142
    1. Yang H. Y., Sun C. C., Wu Y. C., Wang J. D. (2005). Stress, insomnia, and chronic idiopathic urticaria–a case-control study. J. Formos. Med. Assoc. 104, 254–263.
    1. Ying S., Kikuchi Y., Meng Q., Kay A. B., Kaplan A. P. (2002). TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction. J. Allergy Clin. Immunol. 109, 694–700. 10.1067/mai.2002.123236
    1. Zazzali J. L., Broder M. S., Chang E., Chiu M. W., Hogan D. J. (2012). Cost, utilization, and patterns of medication use associated with chronic idiopathic urticaria. Ann. Allergy Asthma Immunol. 108, 98–102. 10.1016/j.anai.2011.10.018
    1. Zhang Q., Wang J., Zhang C., Liao S., Li P., Xu D., et al. . (2016). The components of Huang-Lian-Jie-Du-Decoction act synergistically to exert protective effects in a rat ischemic stroke model. Oncotarget 7, 80872–80887. 10.18632/oncotarget.12645
    1. Zuberbier T., Asero R., Bindslev-Jensen C., Walter Canonica G., Church M. K., Giménez-Arnau A., et al. . (2009). EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 64, 1417–1426. 10.1111/j.1398-9995.2009.02179.x

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa